The prevalence of Prostatism: A Population-Based Survey of Urinary Symptoms

Chute, Christopher G.; Panser, Laurel A.; Girman, Cynthia J.; Öesterling, Joseph E.; Guess, H. A.; Jacobsen, Steven J.; Lieber, Michael

doi:10.1016/s0022-5347(17)35405-8

Cited by 676 publications

(366 citation statements)

References 17 publications

Supporting

Mentioning

329

Contrasting

Unclassified

Order By: Relevance

“…However, only 10 % of men with such symptoms are treated with prescription medications. 14,15 As BPH is underdiagnosed and undertreated, the potential exists for large market expansion through DTCA. 15 Medical therapy for BPH includes alpha 1-adrenergic antagonists (alphablockers), 5-alpha reductase inhibitors (5ARIs), or both in combination.…”

Section: Study Drugsmentioning

confidence: 99%

The Effect of Competing Direct-to-Consumer Advertising Campaigns on the Use of Drugs for Benign Prostatic Hyperplasia: Time Series Analysis

et al. 2014

View full text Add to dashboard Cite

Section: Study Drugsmentioning

confidence: 99%

The Effect of Competing Direct-to-Consumer Advertising Campaigns on the Use of Drugs for Benign Prostatic Hyperplasia: Time Series Analysis

et al. 2014

View full text Add to dashboard Cite

“…1 Community-based studies have evaluated the prevalence of symptomatic BPH or lower urinary tract symptoms (LUTS) by age in several European countries, 2 ± 5 the US 6 and Japan. 7 Results show that one in four men aged 50 y have LUTS, increasing to one in two men aged 65 y.…”

Section: Prevalence Of Bphmentioning

confidence: 99%

BPH in the next millennium:a glimpse to the future

Sancha

1999

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is a highly prevalent, age-related disease. As the world population continues to grow and life expectancy increases, the population of men suffering from BPH will expand. A greater emphasis will be placed on quality of life. The BPH patient of the future will also have greater expectations regarding therapy, which will need to be effective in a shorter period of time. New technologies for the treatment of BPH are anticipated. Already, robot-operated vaporisation of the prostate is being undertaken. With regard to medical therapy, more selective and hence, more effective drugs are under development. With the identi®cation of new a 1 -adrenoceptor subtypes, a-blocker therapy should target the prostate more accurately. Gene-based therapies will have an important role in the future. It is envisaged that technology will exist whereby defective genes can be replaced and gene expression controlled to overcome the disease process. Through pharmacogenomics, drugs will be tailored to the individual, which will, in turn, result in more economical use of medical therapy. Similarly, the development of nanotechnology will allow sitespeci®c delivery of drugs. Together, these advances will make the treatment of BPH even more effective in the new millennium.Keywords: benign prostatic hyperplasia; treatment; pharmacogenomics; nanotechnology; a-blockers Prevalence of BPHBenign prostatic hyperplasia (BPH) is an age-related disease that is highly prevalent, with approximately 90% of men aged over 80 y having histological evidence of the disorder. 1 Community-based studies have evaluated the prevalence of symptomatic BPH or lower urinary tract symptoms (LUTS) by age in several European countries, 2 ± 5 the US 6 and Japan. 7 Results show that one in four men aged 50 y have LUTS, increasing to one in two men aged 65 y.The world population continues to grow by approximately 80 million each year, the equivalent to the current population of Germany, and it is expected to double by the year 2060, reaching a total of 10 billion people (Table 1). 8 This is partly explained by the fact that the world population is ageing, with people enjoying a greater life expectancy. It is currently estimated that each month the population aged b 65 y increases by 800 000. 8 In addition, a signi®cant percentage of men, particularly those living in developed countries, will reach a century. As nearly 50% of men b 65 y are at risk of LUTS suggestive of BPH, with the ageing population, LUTS is set to become even more prevalent in the future. The projected increase in the world male population aged b 65 y, leads to the assumption that, by the year 2010, 115 million men will have LUTS (Table 2). 8 This means that in just 50 years time, there will be three times as many men suffering from BPH. The changing populationWith the technological developments that are ongoing, patients will become better informed about their disease conditions. The Internet as a source of information will continue to evolve and patients will have incre...

show abstract

“…4 These findings were also seen in the Olmsted County Study, in which randomly selected males aged 40-79 years found moderate to severe LUTS increased with age from 26% in men 40-49 years old to 46% in men 70-79 years old. 5 ED, or the inability to obtain and/or maintain an erection suitable for sexual intercourse, also increases in prevalence as men age. The Massachusetts Male Aging Study showed that 52% of men between 40 and 70 years of age experienced some level of ED, from 39% in men in their 40s to 67% in men in their 70s.…”

Section: Introductionmentioning

confidence: 99%

PDE5 inhibitors for LUTS

Mouli

McVary

2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

To review the current literature regarding the relationship between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED), and the role of phosphodiesterase-5 (PDE5) inhibitors for the treatment of LUTS. Review of recently published (1990)(1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009) Keywords: erectile dysfunction; benign prostatic hyperplasia; lower urinary tract symptoms; LUTS; ED IntroductionLower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are highly prevalent in aging males, with a substantial impact on quality of life (QOL). Multiple studies have shown a strong association between these two entities, independent of other risk factors. This relationship may be explained by four interrelated theories: the nitric oxide/cyclic guanosine monophosphate pathway (NO/cGMP), the Rho-kinase pathway, autonomic hyperactivity (AH), and pelvic atherosclerosis. Clinical trials have shown that phosphodiesterase-5 (PDE5)-inhibitor treatment results in significant improvement in LUTS. The exact mechanism of action is not well understood. The results of these studies indicate that PDE5-inhibitor treatment has a role in treating LUTS in the setting of ED. Furthermore, PDE5-inhibitor therapy may expand to treat not only men with ED and/or LUTS, but also LUTS in women.

show abstract

The prevalence of Prostatism: A Population-Based Survey of Urinary Symptoms

Cited by 676 publications

References 17 publications

The Effect of Competing Direct-to-Consumer Advertising Campaigns on the Use of Drugs for Benign Prostatic Hyperplasia: Time Series Analysis

The Effect of Competing Direct-to-Consumer Advertising Campaigns on the Use of Drugs for Benign Prostatic Hyperplasia: Time Series Analysis

BPH in the next millennium:a glimpse to the future

PDE5 inhibitors for LUTS

Contact Info

Product

Resources

About